Sweden · Delayed Price · Currency is SEK Iconovo AB Earnings Call Transcripts
Fiscal Year 2026
-
Revised summary: The company is shifting from a tech platform to monetizing a diverse pipeline of inhaled medicines, including generics and biologics. Regulatory changes and a patent cliff offer market opportunities. Key projects are in licensing and preclinical stages, with partnerships and funding supporting full pharma operations and long-term value.
Fiscal Year 2025
-
Major cost reductions and a shift to a commercial focus defined the quarter, with progress on key projects including EcoPre, EcoRes, and intranasal semaglutide. Regulatory changes have improved prospects for generics, and new board members are driving unified strategic direction.
-
A fully guaranteed SEK 36.6 million rights issue will fund commercialization of inhalation platforms, with a leaner organization and significant cost savings. Focus areas include SymbiCort and Ellipta generics, and intranasal semaglutide, targeting large global markets and aiming for key licensing deals in the next two years.